Lucida Medical, specializing in AI-assisted prostate cancer diagnosis via MRI, raises $11.4M to drive US FDA approval and platform expansion.
Key Details
- 1Lucida Medical, a UK-based AI firm, raised $11.4 million in new funding.
- 2Their Prostate Intelligence (Pi) software uses MRI to help diagnose prostate cancer.
- 3The software is already deployed in up to 15 UK NHS hospitals.
- 4NHS invested around $3 million to use the platform, aiming for diagnoses within 28 days.
- 5The new funds will help pursue US FDA regulatory approval and expand to detect other clinical conditions.
Why It Matters
This funding supports efforts to scale AI-powered prostate cancer diagnosis, addressing critical radiology workforce shortages and speeding up patient pathways. US FDA approval could open access to broader markets and bring innovative diagnostic AI tools to more clinicians and patients.
Source
Radiology Business
Related News
•AuntMinnie
AI Advances in Ultrasound Highlighted at AIUM 2026 Keynote
AI is increasingly enhancing ultrasound imaging, clinical workflows, and education, though challenges in trust and implementation remain.
•AuntMinnie
LLM AI Significantly Boosts MRI Accuracy For Less Experienced Readers
AI LLMs notably improve diagnostic accuracy for less experienced brain MRI readers, with diminishing benefits for experts.
•AuntMinnie
AI Advances in Breast Cancer Risk, CEUS Training Updates, and Imaging AI Variability
This week's top radiology news reviews AI advances in breast and lung cancer risk prediction, new CEUS training standards, and prostate screening updates with imaging modalities.